Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 known ✓ | O60674 | 15/20 | 0.90 |
| ▸ | JAK1 known ✓ | P23458 | 13/20 | 0.90 |
| ▸ | JAK3 known ✓ | P52333 | 10/20 | 0.65 |
| ▸ | TYK2 known ✓ | P29597 | 5/20 | 0.65 |
| ▸ | FGFR1 known ✓ | P11362 | 2/20 | 0.56 |
| ▸ | KIT known ✓ | P10721 | 1/20 | 0.56 |
| ▸ | KDR known ✓ | P35968 | 1/20 | 0.46 |
| ▸ | RET | P07949 | 3/20 | 0.56 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.56 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.56 |
| ▸ | PAK4 | O96013 | 2/20 | 0.56 |
| ▸ | ABL1 | P00519 | 2/20 | 0.56 |
| ▸ | LTK | P29376 | 2/20 | 0.56 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.56 |
| ▸ | CLK2 | P49760 | 2/20 | 0.56 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.56 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.56 |
| ▸ | IKBKE | Q14164 | 2/20 | 0.56 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.56 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL860044 | 1.00 | JAK2 (0.90) | JAK2JAK1JAK3TYK2RET | |
| Phosphoric Acid SCHEMBL859728 | 1.00 | JAK2 (0.90) | JAK2JAK1JAK3TYK2RET | |
| Phosphoric Acid SCHEMBL860421 | 0.97 | JAK2 (0.90) | JAK2JAK1JAK3TYK2RET | |
| Phosphoric Acid SCHEMBL861500 | 0.97 | JAK2 (0.90) | JAK2JAK1JAK3TYK2RET | |
| Phosphoric Acid SCHEMBL860955 | 0.97 | JAK2 (0.90) | JAK2JAK1JAK3TYK2RET | |
| SCHEMBL859844 | 0.95 | JAK2 (1.00) | JAK2JAK1JAK3TYK2RET | |
| SCHEMBL860300 | 0.95 | JAK2 (1.00) | JAK2JAK1JAK3TYK2RET | |
| SCHEMBL859936 | 0.95 | JAK2 (1.00) | JAK2JAK1JAK3TYK2RET | |
| SCHEMBL859886 | 0.92 | JAK2 (1.00) | JAK2JAK1JAK3TYK2RET | |
| SCHEMBL848835 | 0.92 | JAK2 (1.00) | JAK2JAK1JAK3TYK2RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3643312-A1 | 3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]OCTANE- OR HEPTANE-NITRILE AS JAK INHIBITORS | Incyte Holdings Corporation (US) | 2020-04-29 | — | — | EP | claimed |
| EP-2432472-B1 | 3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]OCTANE- OR HEPTANE-NITRILE AS JAK INHIBITORS | INCYTE HOLDINGS CORP (US) | 2019-10-02 | — | — | EP | claimed |
| US-8604043-B2 | 3-[4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors | INCYTE CORPORATION (US) | 2013-12-10 | — | — | US | claimed |
| EP-2432472-A1 | 3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]OCTANE- OR HEPTANE-NITRILE AS JAK INHIBITORS | Incyte Corporation (US) | 2012-03-28 | — | — | EP | claimed |
| WO-2010135621-A1 | 3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]OCTANE- OR HEPTANE-NITRILE AS JAK INHIBITORS | INCYTE CORPORATION (US) | 2010-11-25 | — | — | WO | claimed |
| US-20100298355-A1 | 3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]OCTANE- OR HEPTANE-NITRILE AS JAK INHIBITORS | INCYTE CORPORATION | 2010-11-25 | — | — | US | claimed |
| EP-3643312-A1 | 3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]OCTANE- OR HEPTANE-NITRILE AS JAK INHIBITORS | Incyte Holdings Corporation (US) | 2020-04-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298355-A1 | 3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]OCTANE- OR HEPTANE-NITRILE AS JAK INHIBITORS | JAK1, JAK3, JAK2 | JAK2 3/4885JAK1 1/4885JAK3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.